A
Anaveon
A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients
About Anaveon
Anaveon is a biopharmaceutical startup that focuses on the development of treatments for diseases related to immune system dysfunction. The company was established in 2017 by a group of immunologists and oncologists who are experts in the field of immunotherapy. They aim to utilize engineered cytokines, which are proteins that play a crucial role in cell signaling in the immune system, to create new treatments for diseases that currently have limited treatment options.
Read full description
Anaveon operates in the healthcare market, specifically in the immuno-oncology sector. Its primary clients are patients suffering from diseases such as multiple myeloma and advanced melanoma, which are types of cancer that affect the immune system. The company's business model revolves around the research, development, and eventual commercialization of its treatments. It generates revenue through the funding it receives for its research and the potential sales of its treatments upon successful development and regulatory approval.
The company is currently in the clinical stage, meaning it is testing its treatments in clinical trials. It has presented its preclinical data and ongoing trials at various medical and oncology conferences, including the Society for Immunotherapy of Cancer (SITC) and the European Society for Medical Oncology (ESMO). These presentations are crucial for attracting further funding and partnerships.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Basel, Switzerland
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Digital Therapeutics, Biotech and Pharma, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2021 | $101M | $403M | Pontifax Funds · Pfizer Ventures · Novartis Venture Fund · Cowen Healthcare Investments | ↗ |
| SERIES AOther financing | Feb 2019 | $35M | $25M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Anaveon is 2.1K monthly website visits, up 40% over the last three months. Anaveon's team declined 3.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Forbion Capital Partners
Pontifax Funds- PVPfizer Ventures
Novartis Venture Fund- CICowen Healthcare Investments
Other known investors1 additional known investor
University of Zürich
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anaveon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anaveon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.